 | Up a level |
Journal Article
Al-Sawaf, Othman, Zhang, Can, Lu, Tong, Liao, Michael Z., Panchal, Anesh, Robrecht, Sandra, Ching, Travers 
ORCID: 0000-0002-5577-3516, Tandon, Maneesh, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Boettcher, Sebastian, Kreuzer, Karl-Anton, Chyla, Brenda, Miles, Dale, Wendtner, Clemens-Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael and Fischer, Kirsten
(2021).
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
J. Clin. Oncol., 39 (36).
S. 4049 - 4062.
PHILADELPHIA:
LIPPINCOTT WILLIAMS & WILKINS.
ISSN 1527-7755
Samineni, Divya, Gibiansky, Leonid, Wang, Bei, Vadhavkar, Shweta, Rajwanshi, Richa, Tandon, Maneesh, Sinha, Arijit, Al-Sawaf, Othman, Fischer, Kirsten, Hallek, Michael ORCID: 0000-0002-7425-4455, Salem, Ahmed Hamed, Li, Chunze and Miles, Dale
(2022).
Pharmacokinetics and Exposure-Response Analysis of Venetoclax plus Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
Adv. Ther., 39 (8).
S. 3635 - 3654.
NEW YORK:
SPRINGER.
ISSN 1865-8652